Observational study finds tadalafil use associated with 22% increased glaucoma risk — Evidence Review
Published in British Journal of Ophthalmology, by researchers from British Journal of Ophthalmology
Researched by
— the AI search engine for science
Table of Contents
A large observational study suggests that long-term use of tadalafil (Cialis) for urinary symptoms may be linked to a modestly increased risk of glaucoma, though most previous research has found only minor, often reversible, eye side effects with PDE5 inhibitors. While related studies offer mixed evidence, some report associations between prolonged PDE5 inhibitor use and increased glaucoma prevalence, supporting the need for further investigation, as discussed in the original study published in Ophthalmology Times.
- Several large reviews and clinical trials found no conclusive evidence that PDE5 inhibitors like tadalafil directly cause vision-threatening ocular events, with minor visual side effects generally being transient and reversible 1 2 6 7 10 11.
- However, epidemiological and cross-sectional studies have reported higher rates of self-reported glaucoma or ocular hypertension among long-term users of drugs like sildenafil and tadalafil, suggesting that a subgroup of patients or those with additional risk factors may be more susceptible 4 5.
- The new study is notable for its large sample size and focus on long-term, daily use for non-erectile dysfunction indications, a scenario less frequently addressed in earlier research; related studies emphasize the importance of monitoring eye health in higher-risk populations 3 5.
Study Overview and Key Findings
Glaucoma is a leading cause of irreversible blindness worldwide, and identifying modifiable risk factors remains a public health priority. Tadalafil, a long-acting phosphodiesterase type 5 inhibitor (PDE5i), is not only widely prescribed for erectile dysfunction but is also used chronically to treat urinary symptoms associated with benign prostatic hyperplasia (enlarged prostate). Given the drug’s widespread use and the mixed evidence on its ocular safety, this new study addresses a significant clinical question: does long-term tadalafil use increase the risk of glaucoma or related eye conditions when used for urinary symptoms?
The study stands out for its large cohort, careful matching of participants to control for confounding variables, and specific focus on chronic, daily tadalafil use—an area where previous research has been limited. The findings have direct implications for patient counseling and clinical monitoring.
| Property | Value |
|---|---|
| Organization | British Journal of Ophthalmology |
| Journal Name | British Journal of Ophthalmology |
| Population | Men aged 40 or older |
| Sample Size | n=73,854 |
| Methods | Observational Study |
| Outcome | Glaucoma, ocular hypertension, treatment initiation for glaucoma |
| Results | Men prescribed tadalafil had a 22% higher glaucoma risk. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus database, which contains over 200 million research papers, using targeted search queries. The following queries were used to identify relevant studies:
- Cialis glaucoma risk men
- tadalafil ocular health studies
- erectile dysfunction medications eye effects
Below, we synthesize key findings from related research, organized by major topics:
| Topic | Key Findings |
|---|---|
| What are the long-term ocular risks of PDE5 inhibitors like tadalafil? | - Most studies report transient, reversible minor eye side effects with PDE5 inhibitors, and large reviews find no conclusive evidence of vision-threatening complications or long-term ocular toxicity 1 2 6 7 10 11. - Some large epidemiological and cross-sectional studies report greater prevalence of glaucoma or ocular hypertension among long-term users 4 5. |
| Do PDE5 inhibitors increase intraocular pressure or glaucoma risk? | - Short-term use of sildenafil or tadalafil does not appear to meaningfully affect intraocular pressure in healthy men or those with controlled glaucoma 2 6. - Case reports, systematic reviews, and epidemiological analyses have linked prolonged or frequent use to higher odds of developing glaucoma or ocular hypertension in some populations 4 5 3. |
| How should clinicians manage ocular risks in patients using PDE5 inhibitors? | - Several reviews recommend baseline eye exams and regular follow-up for patients with glaucoma risk factors who require prolonged PDE5 inhibitor therapy, especially with daily or high-dose regimens 5 3. - Physicians are advised to counsel patients to report any sudden changes in vision and discontinue use if serious symptoms occur 7 9. |
What are the long-term ocular risks of PDE5 inhibitors like tadalafil?
The new study’s finding of a modestly increased glaucoma risk among chronic tadalafil users aligns with some earlier epidemiological analyses but contrasts with much of the clinical trial and review literature, which generally report only minor, reversible visual side effects and no clear evidence of long-term ocular harm for most users. However, existing clinical trials are often short-term or underpowered to detect rare events.
- Most clinical trials and systematic reviews show that PDE5 inhibitors, including tadalafil and sildenafil, cause only mild, short-lived visual disturbances, such as altered color vision or increased light sensitivity, affecting a minority of users 1 2 6 7 10 11.
- Large reviews have not established a direct causal relationship between PDE5 inhibitor use and vision-threatening complications, but rare case reports of ischemic optic neuropathy, retinal vein occlusion, and other serious events have been described 1 3 7 9.
- Epidemiological studies and cross-sectional analyses in the U.S. have reported higher rates of self-reported glaucoma among long-term sildenafil or PDE5 inhibitor users, supporting the possibility of increased risk in some populations 4 5.
- Animal studies and long-term toxicology data generally show no evidence of cumulative retinal damage with chronic PDE5 inhibition 11.
Do PDE5 inhibitors increase intraocular pressure or glaucoma risk?
Short-term studies in healthy volunteers and patients with controlled glaucoma generally find no significant impact of sildenafil or tadalafil on intraocular pressure (IOP). However, some population-based studies and case reports suggest that long-term, frequent, or high-dose use may be associated with higher IOP and increased risk of glaucoma or ocular hypertension.
- Randomized trials show no clinically significant change in IOP or pupil diameter after single or multiple doses of sildenafil or tadalafil over several months 2 6.
- Systematic reviews and narrative reviews highlight a need for larger, longer studies to clarify whether chronic PDE5 inhibition modifies ocular physiology or increases glaucoma risk over time, especially in susceptible individuals 3 8.
- Prolonged use of PDE5 inhibitors, especially in those with other glaucoma risk factors, has been linked to a greater prevalence of self-reported glaucoma in some cross-sectional and epidemiologic studies 4 5.
- Minor increases in IOP have been documented in some case reports and small studies, but these are generally transient and reversible 10.
How should clinicians manage ocular risks in patients using PDE5 inhibitors?
Given the widespread use of PDE5 inhibitors and the potential for ocular side effects in high-risk populations, several reviews recommend a cautious clinical approach, particularly for patients with pre-existing glaucoma risk factors or those requiring long-term, daily therapy.
- Clinical guidelines and expert reviews suggest baseline eye screening and regular ophthalmologic monitoring for patients starting long-term or high-dose PDE5 inhibitors, such as tadalafil for urinary symptoms, especially when other risk factors are present 5 3.
- Patients should be counseled to promptly report any visual changes, and clinicians should be vigilant for rare but serious ocular complications 7 9.
- The new study reinforces these recommendations by documenting an association between chronic tadalafil use and increased glaucoma risk, supporting the need for targeted screening and follow-up in higher-risk groups 5.
- Existing evidence does not support discontinuing PDE5 inhibitors in all patients, but individualized risk assessment is warranted 3 5 7.
Future Research Questions
While the current evidence points to a possible association between long-term tadalafil use and increased glaucoma risk, causality remains unproven and the mechanisms are not fully understood. Future research should address these gaps through well-designed prospective studies, mechanistic investigations, and targeted clinical monitoring protocols.
| Research Question | Relevance |
|---|---|
| Does long-term tadalafil use directly increase the risk of developing glaucoma? | Establishing causality is essential for clinical decision-making. Most existing studies are observational or cross-sectional and cannot definitively demonstrate cause and effect 1 4 5. |
| What mechanisms might link PDE5 inhibitor use to ocular hypertension or glaucoma? | Understanding underlying biological pathways could clarify which patients are at risk and help identify preventive strategies. Current studies speculate on changes in ocular perfusion, but data are limited 3 8. |
| Are certain populations or risk groups more susceptible to ocular side effects from PDE5 inhibitors? | Identifying high-risk groups (e.g., those with family history, high myopia, or ocular hypertension) would allow for targeted screening and safer prescribing 3 5. |
| Does the risk of glaucoma differ between PDE5 inhibitors (sildenafil vs. tadalafil) or with different dosing regimens? | Most existing studies focus on sildenafil or do not distinguish between different PDE5 inhibitors or usage patterns; understanding these distinctions could refine risk assessments and prescribing practices 4 5 6. |
| What are the benefits and risks of routine eye screening for patients on long-term PDE5 inhibitors? | Evidence-based screening protocols are lacking, and further research could optimize monitoring strategies, balancing early detection with cost-effectiveness and patient burden 5 3. |
This comprehensive review underscores the importance of continued evaluation of ocular risks associated with long-term PDE5 inhibitor use, particularly in patients with additional glaucoma risk factors. While current evidence does not mandate discontinuation of these medications, individualized risk assessment and monitoring may help mitigate potential adverse outcomes.